On TRAC with charity donations

Cornish Regulatory Affairs Specialist raises £20,000 through volunteer project

TRAC Services has donated more than £20,000 to local charities, clubs and community projects in Cornwall through a special volunteer project.

The Camborne, UK-based company, which works with pharmaceutical manufacturers around the world, has donated £22,000 since launching a pioneering project in 2006 in which volunteers across Cornwall raised funds for a charity or community group in return for a 30-minute question and answer session.

The project was launched four years ago to enable pharmaceutical companies to get feedback on Patient Information Leaflets from members of the public, and gave everyone taking part the opportunity to raise money by donating £20 to a nominated charity or group.

More than 50 community groups such as Cornwall Blind Association, St Agnes Football Club, Truro Fencing Club, Cornwall Air Ambulance, and Camborne Bowling Association have all had their funds boosted by the volunteer scheme.

TRAC Director Sarah Trethowan said: ‘When we came up with the idea of running the volunteer project we really didn’t know if it would take off, but are absolutely thrilled that we have been able to donate £22,000 to good causes and community projects in Cornwall.

‘The beauty of the volunteer project was that not only did every person taking part in it raise £20 towards their nominated cause but by taking part they were also helping to improve the way pharmaceutical companies produce information leaflets, making them clearer and easier to understand.’

With the project now coming to an end, TRAC is continuing its charity work by becoming a member of Cornwall Community Foundation’s 100 Club, which has been launched to enable businesses in the county to help fund grassroots organisations and projects.

TRAC recently became the second firm in Cornwall to achieve a Silver Investors in People (IIP) standard. It also took top honours in the Graduate Development Category at the Cornwall Excellence in Business Training Awards 2010.

You may also like

Packaging

Amarox recalls sertraline batch after citalopram blister strips found inside sealed cartons

The MHRA has issued a class two recall of one batch of Amarox's sertraline 100 mg film-coated tablets following a secondary packaging error that resulted in citalopram 40 mg blister strips being included in sealed cartons
Regulatory

MHRA report shows agency met targets and closed year in financial surplus

The UK government agency has reported meeting or exceeding every statutory performance target in the 2025/26 financial year, closing in financial surplus while advancing clinical trials reform and AI regulation
Regulatory

FDA approves AstraZeneca's Breztri Aerosphere as first single-inhaler triple therapy for asthma

AstraZeneca has received FDA approval to extend Breztri Aerosphere's indication to include maintenance treatment of asthma in patients aged 12 and older, based on Phase III KALOS and LOGOS trial data showing statistically significant improvements in lung function
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Regulatory

FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus

AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Subscribe now